category:news - GLP1 Guide (Page 3)

category:news

A collection of 68 posts

Why the Tirzepatide shortage ending might be bad news.

Why the Tirzepatide shortage ending might be bad news.

Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.

GLP1s and Sleep Apnea

GLP1s and Sleep Apnea

GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea

Insurers continue to embrace Virtual Healthcare for GLP1s

Insurers continue to embrace Virtual Healthcare for GLP1s

Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.

Novo's CEO will testify, but change is unlikely

categeory:watercooler

Novo's CEO will testify, but change is unlikely

Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.

Amgen's GLP1: MariTide (formerly AMG-133)

Amgen's GLP1: MariTide (formerly AMG-133)

Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.

Eli Lilly's other new GLP1 - Orforglipron

company:eli-lilly

Eli Lilly's other new GLP1 - Orforglipron

Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.

23andMe gets into GLP1

23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.

Novo's new GLP1: Amycretin

Novo's new GLP1: Amycretin

Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.

GLP1's effect on ADHD

GLP1's effect on ADHD

What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.

A new GLP1: Retatrutide

A new GLP1: Retatrutide

Is mimicking more hormones better? Let's find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist

Are GLP1s primarily brain drugs?

Are GLP1s primarily brain drugs?

Are GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc) primarily brain drugs?

Eli Lilly China approval and new suppliers

company:eli-lilly

Eli Lilly China approval and new suppliers

As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.

Pfizer's GLP1: Danuglipron

drug:danuglipron

Pfizer's GLP1: Danuglipron

Read more about Dangulipron, Pfizer's GLP1 receptor agonist. Will it be better than Ozempic, Wegovy, Mounjaro, Zepbound and others?

Victoza (Liraglutide) Generic hits the market

Teva Pharmaceuticals has started manufacturing a Victoza generic drug (liraglutide), and it's available inside the United States.

Nestle's Vital Pursuit for GLP1 users

Nestle's Vital Pursuit for GLP1 users

The trend of companies riding the GLP1 wave continues -- Nestle introduces a new food line that is aimed at attracting GLP1 users.

chemical:servodutide

Survodutide Phase 2 Trial Results

Survodutide is a dual Glucagon and Glucagon-Like Peptide 1 agonist which interacts with hormone receptors in your body to help reduce food cravings, and encourage weight loss. 🍃Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work? Check out our

Senior citizens and GLP1 Receptor Agonists

user:senior-citizens

Senior citizens and GLP1 Receptor Agonists

Senior citizens are adopting and starting to use GLP1 Receptor Agonists in droves. 🍃Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work? Check out our quick explainer Based on data from 2023, over 1 in 4 people who were

FDA approves Wegovy for reducing heart disease risk

drug:wegovy Featured

FDA approves Wegovy for reducing heart disease risk

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or OverweightThe FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.FDAOffice of the Commissioner In great